NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

阿茲海默症治療藥及治療設備的全球市場:∼2027年

Global Alzheimer's Treatment Market Outlook 2027

出版商 Research Nester 商品編碼 946861
出版日期 內容資訊 英文 163 Pages
商品交期: 最快1-2個工作天內
價格
阿茲海默症治療藥及治療設備的全球市場:∼2027年 Global Alzheimer's Treatment Market Outlook 2027
出版日期: 2020年06月01日內容資訊: 英文 163 Pages
簡介

全球阿茲海默症治療藥及治療設備的市場在預測期間內預計將以約7.44%的年複合成長率發展,2027年終約成長到20億817萬美元的規模。根據阿茲海默症協會指出,美國65歲以上估計有580萬人患阿茲海默症疾病,這個數目預計2050年增加到1380萬人。

本報告提供全球阿茲海默症治療藥及治療設備的市場調查,市場定義和概要,市場成長的各種影響因素分析,疫情趨勢,技術、專利分析,臨床試驗分析,市場規模的變化、預測,藥物類型、設備類型、通路、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊彙整。

目錄

第1章 簡介

第2章 前提條件、縮寫

第3章 調查手法

第4章 摘要整理

第5章 市場動態

  • 成長推動因素
  • 主要趨勢

第6章 主要市場機會

第7章 促進市場成長的主要障礙

第8章 法規情形

第9章 產業風險分析

  • 需求風險分析
  • 供給風險分析

第10章 流行病學分析

第11章 專利分析

第12章 臨床試驗分析

第13章 開發中的治療設備比較分析

第14章 市場預測:各種區分

  • 市場規模、預測
  • 治療藥:各種區分
      • 單劑藥
        • 膽鹼酯酶抑製劑
          • Donepezil (Aricept)
          • Galantamine (Razadyne)
          • Rivastigmine (Exelon)
        • N-甲基-D-天冬氨酸(Nmda)拮抗劑
      • 並用藥
      • 線上
      • 離線
        • 院內藥局
        • 零售藥局
  • 醫療設備:各種區分
      • 穿戴式設備
      • 非穿戴式設備
      • 醫院
      • 診所
      • 特別護養養老院
      • 居家醫療
  • 治療藥、醫療設備:各地區、主要國家
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲

第15章 競爭結構

  • 概要
  • 市場佔有率
  • 主要產品的評估
  • 成長策略分析
  • 主要的聯盟、JV
  • 主要的M&A
  • 最近的新聞、展開
  • 主要的客戶、合作夥伴
  • 主要財務指標相關分析
  • 主要企業簡介
    • Neuroem Therapeutics, Inc.
    • Neuronix
    • Daiichi Sankyo Company Limited
    • H. Lundbeck A/S
    • Pfizer Inc.
    • Abbvie Inc
    • Eli Lilly And Company
    • Allergan, Inc.
    • Janssen Pharmaceuticals, Inc.

第16章 建議

目錄

According to the Alzheimer's Association in 2020, an estimated 5.8 million people above the age of 65 in America are living with Alzheimer's disease. This number is further predicted to increase to 13.8 million people above the age of 65 by 2050. Alzheimer's disease is a neurological disorder which commonly occurs among the older population. The disease is characterized by the gradual degeneration of the brain tissue, which leads to temporary or permanent loss of memory. The Alzheimer's treatment market is anticipated to grow at a CAGR of about 7.44% over the forecast period, i.e., 2020-2027. The market is further projected to attain a market value of around USD 2,008.17 million by the end of 2027.

The market for Alzheimer's treatment is segmented by drug class, by distribution channel, by product, by end user and by region. On the basis of distribution channel, the market is segmented into online and offline segment. The offline segment is further segmented into hospital pharmacy and retail pharmacy, out of which, the offline distribution channel is anticipated to hold the leading share in the market on account of larger presence of hospital and retail pharmacies globally. On the other hand, the segment for online distribution channel is predicted to grow at the highest CAGR during the forecast period on account of rising demand for online pharmacies and various advancements in the e-commerce industry. The preference for online pharmacies is estimated to increase among the patients on account of various factors such as ease and convenience, confidentiality, low cost, and others.

Based on region, the Alzheimer's treatment market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in North America is anticipated to hold the major share of Alzheimer's treatment market on account of increasing incidences of the disease. Moreover, the presence of key players in the region is another factor predicted to lead to the growth of North America Alzheimer's treatment market in the coming years. The market in Europe is estimated to witness significant growth and hold a vast potential for the development of the Alzheimer's treatment market on the back of its increasing geriatric population.

Some of the key industry leaders in the global Alzheimer's treatment market are: NeuroEM Therapeutics, Inc., AbbVie Inc., Allergan Inc., H. Lundbeck A/S, Janssen, Eli Lilly and Company, Daiichi Sankyo Company Limited, Eisai Co., Ltd. And Neuronix.

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation
  • 1.3. Product Overview

2. Assumptions And Acronyms

3. Research Methodology

  • 3.1. Research Process
  • 3.2. Primary Research
    • Manufacturer Front
    • Supplier/Distributor Front
    • End User Front
  • 3.3. Secondary Research
  • 3.4. Market Size Estimation

4. Executive Summary- Global Alzheimer's Treatment Market

5. Analysis Of Market Dynamics

  • 5.1. Growth Drivers
  • 5.2. Key Trends

6. Key Market Opportunities

7. Major Roadblocks For The Market Growth

8. Regulatory Landscape

9. Industry Risk Analysis

  • 9.1. Demand Risk Analysis
  • 9.2. Supply Risk Analysis

10. Epidemiology Analysis

11. Patent Analysis

12. Clinical Trials Analysis

13. Comparative Analysis Of Treatment Devices In Development

14. Global Alzheimer's Treatment Market Outlook

  • 14.1. Market Size And Forecast, 2018-2027
  • 14.1.1. By Value (USD Million)
  • 14.2. Global Alzheimer's Treatment Market Segmentation, 2018-2027
    • 14.2.1. By Treatment
      • 14.2.1.1. By Drug Class
        • Standalone Drugs, 2018-2027 (USD Million)
          • Cholinesterase Inhibitors, 2018-2027 (USD Million)
            • Donepezil (Aricept), 2018-2027 (USD Million)
            • Galantamine (Razadyne), 2018-2027 (USD Million)
            • Rivastigmine (Exelon), 2018-2027 (USD Million)
          • N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
        • Combination Drugs, 2018-2027 (USD Million)
      • 14.2.1.2. By Distribution Channel
        • Online, 2018-2027 (USD Million)
        • Offline, 2018-2027 (USD Million)
          • Hospital Pharmacy, 2018-2027 (USD Million)
          • Retail Pharmacy, 2018-2027 (USD Million)
    • 14.2.2. By Medical Device
      • 14.2.2.1. By Product
        • Wearable Device, 2018-2027 (USD Million)
        • Non-Wearable Device, 2018-2027 (USD Million)
      • 14.2.2.2. By End-User
        • Hospitals, 2018-2027 (USD Million)
        • Clinics, 2018-2027 (USD Million)
        • Nursing Homes, 2018-2027 (USD Million)
        • Home-Care Settings, 2018-2027 (USD Million)
    • 14.2.3. By Region
      • 14.2.3.1. North America Alzheimer's Treatment Market, 2018-2027 (USD Million)
        • 14.2.3.1.1. Market Overview
        • 14.2.3.1.2. Market Size, 2018-2027 (USD Million)
        • 14.2.3.1.3. Assessment Of Macroeconomic Factors
        • 14.2.3.1.4. Market Segmentation
          • By Treatment
          • By Drug Class
            • Standalone Drugs, 2018-2027 (USD Million)
              • Cholinesterase Inhibitors, 2018-2027 (USD Million)
                • Donepezil (Aricept), 2018-2027 (USD Million)
                • Galantamine (Razadyne), 2018-2027 (USD Million)
                • Rivastigmine (Exelon), 2018-2027 (USD Million)
              • N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
            • Combination Drugs, 2018-2027 (USD Million)
          • By Distribution Channel
            • Online, 2018-2027 (USD Million)
            • Offline, 2018-2027 (USD Million)
              • Hospital Pharmacy, 2018-2027 (USD Million)
              • Retail Pharmacy, 2018-2027 (USD Million)
          • By Medical Device
          • By Product
            • Wearable Device, 2018-2027 (USD Million)
            • Non-Wearable Device, 2018-2027 (USD Million)
          • By End-User
            • Hospitals, 2018-2027 (USD Million)
            • Clinics, 2018-2027 (USD Million)
            • Nursing Homes, 2018-2027 (USD Million)
            • Home-Care Settings, 2018-2027 (USD Million)
          • By Country
            • Us, 2018-2027 (USD Million)
            • Canada, 2018-2027 (USD Million)
      • 14.2.3.2. Europe Alzheimer's Treatment Market, 2018-2027 (USD Million)
        • 14.2.3.2.1. Market Overview
        • 14.2.3.2.2. Market Size, 2018-2027 (USD Million)
        • 14.2.3.2.3. Assessment Of Macroeconomic Factors
        • 14.2.3.2.4. Market Segmentation
          • By Treatment
          • By Drug Class
            • Standalone Drugs, 2018-2027 (USD Million)
              • Cholinesterase Inhibitors, 2018-2027 (USD Million)
                • Donepezil (Aricept), 2018-2027 (USD Million)
                • Galantamine (Razadyne), 2018-2027 (USD Million)
                • Rivastigmine (Exelon), 2018-2027 (USD Million)
              • N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
            • Combination Drugs, 2018-2027 (USD Million)
          • By Distribution Channel
            • Online, 2018-2027 (USD Million)
            • Offline, 2018-2027 (USD Million)
              • Hospital Pharmacy, 2018-2027 (USD Million)
              • Retail Pharmacy, 2018-2027 (USD Million)
          • By Medical Device
          • By Product
            • Wearable Device, 2018-2027 (USD Million)
            • Non-Wearable Device, 2018-2027 (USD Million)
          • By End-User
            • Hospitals, 2018-2027 (USD Million)
            • Clinics, 2018-2027 (USD Million)
            • Nursing Homes, 2018-2027 (USD Million)
            • Home-Care Settings, 2018-2027 (USD Million)
          • By Country
            • Uk, 2018-2027 (USD Million)
            • Germany, 2018-2027 (USD Million)
            • Italy, 2018-2027 (USD Million)
            • France, 2018-2027 (USD Million)
            • Spain, 2018-2027 (USD Million)
            • Russia, 2018-2027 (USD Million)
            • Rest Of Europe, 2018-2027 (USD Million)
      • 14.2.3.3. Asia Pacific Alzheimer's Treatment Market, 2018-2027 (USD Million)
        • 14.2.3.3.1. Market Overview
        • 14.2.3.3.2. Market Size, 2018-2027 (USD Million)
        • 14.2.3.3.3. Assessment Of Macroeconomic Factors
        • 14.2.3.3.4. Market Segmentation
          • By Treatment
          • By Drug Class
            • Standalone Drugs, 2018-2027 (USD Million)
              • Cholinesterase Inhibitors, 2018-2027 (USD Million)
                • Donepezil (Aricept), 2018-2027 (USD Million)
                • Galantamine (Razadyne), 2018-2027 (USD Million)
                • Rivastigmine (Exelon), 2018-2027 (USD Million)
              • N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
            • Combination Drugs, 2018-2027 (USD Million)
          • By Distribution Channel
            • Online, 2018-2027 (USD Million)
            • Offline, 2018-2027 (USD Million)
              • Hospital Pharmacy, 2018-2027 (USD Million)
              • Retail Pharmacy, 2018-2027 (USD Million)
          • By Medical Device
          • By Product
            • Wearable Device, 2018-2027 (USD Million)
            • Non-Wearable Device, 2018-2027 (USD Million)
          • By End-User
            • Hospitals, 2018-2027 (USD Million)
            • Clinics, 2018-2027 (USD Million)
            • Nursing Homes, 2018-2027 (USD Million)
            • Home-Care Settings, 2018-2027 (USD Million)
          • By Country
            • China, 2018-2027 (USD Million)
            • India, 2018-2027 (USD Million)
            • Japan, 2018-2027 (USD Million)
            • South Korea, 2018-2027 (USD Million)
            • Indonesia, 2018-2027 (USD Million)
            • Australia, 2018-2027 (USD Million)
            • Rest Of Asia Pacific, 2018-2027 (USD Million)
      • 14.2.3.4. Latin America Alzheimer's Treatment Market, 2018-2027 (USD Million)
        • 14.2.3.4.1. Market Overview
        • 14.2.3.4.2. Market Size, 2018-2027 (USD Million)
        • 14.2.3.4.3. Assessment Of Macroeconomic Factors
        • 14.2.3.4.4. Market Segmentation
          • By Treatment
          • By Drug Class
            • Standalone Drugs, 2018-2027 (USD Million)
              • Cholinesterase Inhibitors, 2018-2027 (USD Million)
                • Donepezil (Aricept), 2018-2027 (USD Million)
                • Galantamine (Razadyne), 2018-2027 (USD Million)
                • Rivastigmine (Exelon), 2018-2027 (USD Million)
              • N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
            • Combination Drugs, 2018-2027 (USD Million)
          • By Distribution Channel
            • Online, 2018-2027 (USD Million)
            • Offline, 2018-2027 (USD Million)
              • Hospital Pharmacy, 2018-2027 (USD Million)
              • Retail Pharmacy, 2018-2027 (USD Million)
          • By Medical Device
          • By Product
            • Wearable Device, 2018-2027 (USD Million)
            • Non-Wearable Device, 2018-2027 (USD Million)
          • By End-User
            • Hospitals, 2018-2027 (USD Million)
            • Clinics, 2018-2027 (USD Million)
            • Nursing Homes, 2018-2027 (USD Million)
            • Home-Care Settings, 2018-2027 (USD Million)
          • By Country
            • Brazil, 2018-2027 (USD Million)
            • Mexico, 2018-2027 (USD Million)
            • Rest Of Latin America, 2018-2027 (USD Million)
      • 14.2.3.5. Middle East & Africa Alzheimer's Treatment Market, 2018-2027 (USD Million)
        • 14.2.3.5.1. Market Overview
        • 14.2.3.5.2. Market Size, 2018-2027 (USD Million)
        • 14.2.3.5.3. Assessment Of Macroeconomic Factors
        • 14.2.3.5.4. Market Segmentation
          • By Treatment
          • By Drug Class
            • Standalone Drugs, 2018-2027 (USD Million)
              • Cholinesterase Inhibitors, 2018-2027 (USD Million)
                • Donepezil (Aricept), 2018-2027 (USD Million)
                • Galantamine (Razadyne), 2018-2027 (USD Million)
                • Rivastigmine (Exelon), 2018-2027 (USD Million)
              • N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
            • Combination Drugs, 2018-2027 (USD Million)
          • By Distribution Channel
          • By Product
          • By End-User
          • By Country
            • Israel, 2018-2027 (USD Million)
            • Saudi Arabia, 2018-2027 (USD Million)
            • UAE, 2018-2027 (USD Million)
            • South Africa, 2018-2027 (USD Million)
            • Rest Of Middle East & Africa, 2018-2027 (USD Million)

15. Competitive Structure

  • 15.1. Detailed Overview
  • 15.2. Market Share
  • 15.3. Assessment Of Key Product Offerings
  • 15.4. Analysis Of Growth Strategies
  • 15.5. Key Collaborations And Joint Ventures
  • 15.6. Key Mergers And Acquisitions
  • 15.7. Recent News And Developments
  • 15.8. Key Clients And Partners
  • 15.9. Exhaustive Analysis On Key Financial Indicators
  • 15.10. Company Profiles Of Global Alzheimer's Treatment Market
    • 15.10.1. Neuroem Therapeutics, Inc.
    • 15.10.2. Neuronix
    • 15.10.3. Daiichi Sankyo Company Limited
    • 15.10.4. H. Lundbeck A/S
    • 15.10.5. Pfizer Inc.
    • 15.10.6. Abbvie Inc
    • 15.10.7. Eli Lilly And Company
    • 15.10.8. Allergan, Inc.
    • 15.10.9. Janssen Pharmaceuticals, Inc.
    • 15.10.10. Other Market Players Strategic

16. Recommendations